ClinicalTrials.gg
RecruitingNCT05887661Updated Nov 12, 2026

Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy

An interventional study of hypovolemic phlebotomy in Hepatocellular Carcinoma, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled May 2022, registered Mar 2023).
  • Started May 2022; still recruiting 4 years 6 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
318th of 1,038
160 · median 77
Started
2022
with 110 others
No phase
236 of 1,314
75 open now
Primary completion
2026-08
later than 255 of 560 live
Registered
803rd of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 318th largest by planned enrollment of the 1,038 interventional ones that give a count, is one of 111 that started in 2022, is one of 236 with no phase, reaches primary completion later than 255 of the 560 other live ones, and was the 803rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

484 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about goal-directed LCVP based on hypovolemic phlebotomy (HP) in laparoscopic hepatectomy. The main questions it aims to answer are:

  1. The safety and feasibility of HP
  2. To evaluate whether HP can reduce perioperative blood transfusion ratio Participants undergoing liver resection with HP was performed by the anesthesiologist. Blood was withdrawn approximately 30 min prior to the initiation of liver parenchymal transection from central venous. The aim was to maintain the CVP between 0 to 5 cmH2O. HP volume was 5-10 mL/kg of patient body weight, generally. Participants in control group undergoing liver resection without HP.
03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • hypovolemic phlebotomy
  • low central venous pressure
  • goal-directed
  • laparoscopic hepatectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Hepatocellular Carcinoma
  • Preference for laparoscopic hepatectomy and patient agreement

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Pregnancy
  • Refusal of blood product transfusion
  • Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure)
  • History of significant cerebrovascular disease
  • Restrictive or obstructive pulmonary disease
  • Uncontrolled hypertension
  • Renal dysfunction ( \<60 mL/min),
  • \<100 g/L
  • Abnormal coagulation values ( >1.5 not on warfarin and/or count \<100 ×109/L)
  • Evidence of hepatic metabolic disorder ( >35 mmol/L)
  • Presence of active infection
  • Preoperative autologous blood donation
  • Patients were not allowed to receive erythropoietin at any time during the index hospitalization.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    hypovolemic phlebotomy (HP)

    patients in this group undergoing laparoscopic hepatectomy was performed with goal-directed LCVP based on hypovolemic phlebotomy (HP)

    Procedure: hypovolemic phlebotomy

  • No intervention
    Control

    patients in this group undergoing laparoscopic hepatectomy was performed with LCVP but no hypovolemic phlebotomy (HP)

Interventions

  • Procedurehypovolemic phlebotomy

    hypovolemic phlebotomy was performed after induction of anesthesia and before the star of parenchymal division, with a goal-directed low central venous pressure drop to 5mmHg.

    Also known as: HP

06

What researchers measure

Primary outcomes

  1. The proportion of allogeneic red blood cell products transfusion

    The primary end point of the study was the proportion of patients who required transfusion of allogeneic red blood cell products during laparoscopic hepatectomy or at any time during the hospitalization during the index admission.

    Time frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.

Secondary outcomes

  1. The volume of Phlebotomy

    Time frame: From the start of operation until the end of operation.

  2. The volume of Intraoperative blood loss

    Time frame: From the start of operation until the end of operation (during the operation).

  3. The volume of Allogeneic transfusion (perioperative)

    Time frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.

  4. The volume of Allogeneic transfusion (postoperative)

    Time frame: From the end of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.

  5. The volume of Allogeneic transfusion (intraoperative)

    Time frame: From the start of operation until the end of operation.

  6. The volume of Fresh frozen plasm (FFP) transfusion

    Time frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.

  7. The volume of Platelets transfusion

    Time frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.

  8. The volume of Albumin transfusion

    Time frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.

  9. Perioperative lowest concentration of Hb

    Time frame: From the start of operation until the date of discharge from hospital or date of death from any cause, whichever came first. assessed up to 12 months.

  10. Pre-transection central venous pressure (CVP), (basic CVP)

    Time frame: From the start of anesthesia induction until the star of operation.

  11. Lowest central venous pressure (CVP)

    Time frame: From the start of operation until the end of operation (during the operation).

  12. time of pringle maneuver

    Time frame: From the start of operation until the end of operation.

  13. number of pringle maneuver

    how many patients have the pringle maneuver

    Time frame: From the start of operation until the end of operation.

  14. operating time

    Time frame: From the start of operation until the end of operation.

  15. The proportion of laparoscopic hepatectomy converted to open liver resection

    Time frame: From the start of operation until the end of operation.

  16. Length of stay

    Time frame: From date of hospitalization until the date of discharge from hospital or date of death from any cause, whichever came first. assessed up to 12 months

  17. Number of Participants with postoperative complications (overall)

    Time frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Aug 2026, 51 months.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's 51 months is close to that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jan 2026 → Aug 2026 and completion May 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2023
First posted
Jun 5, 2023
StartActual
May 1, 2022
Primary completionActual
Aug 1, 2026was Jan 2026
CompletionEst.
Dec 1, 2026was May 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 1, 2026→Aug 1, 2026 (actual)
Nov 12, 2026
Study completion
May 1, 2026→Dec 1, 2026
Nov 12, 2026
Enrollment
100→160
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Jan 1, 2026→Aug 1, 2026 (now actual)
    Study completion May 1, 2026→Dec 1, 2026
    Enrollment 100→160
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05887661
Responsible party
Shijiang Liu, MD (Clinical Professor, The First Affiliated Hospital with Nanjing Medical University) — Principal investigator
First posted
Jun 5, 2023
Start date
May 1, 2022
Primary completion
Aug 1, 2026
Completion
Dec 1, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Shijiang Liu, MD
Contact
liushijiang@jsph.org.cn
+862568303569
Yue Wang
Contact
jsphkjwy@163.com
+862568136360
Shijiang Liu, MD
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion